

F. No. 15(4)/2016/Div. III/NPPA
National Pharmaceutical Pricing Authority
Department of Pharmaceuticals
Ministry of Chemicals & Fertilizers
Government of India
Ph: 23345120 Fax: 23345119
Website: www.nppaindia.nic.in

5th /3rd Floor,
YMCA Cultural Centre Building,
1, Jai Singh Road, N. Delhi- 110001.
Date: 3.10.2016

Office Memorandum


This office has been receiving complaints regarding shortage of Penicillamine drug (used for treatment of Wilson's disease) from different parts of the country in the last two months.

Under the provisions of DPCO, 2013, the NPPA is mandated to monitor the production and availability of scheduled formulations and the active pharmaceutical ingredients contained therein; and the manufacturer of scheduled formulations and active pharmaceutical ingredients contained in the scheduled formulations are required to furnish information regarding production / import and sale of drugs specified under National List of Essential Medicines in Form III of Schedule – II of DPCO, 2013 on quarterly basis.

As per the records available with this office, the subject drug is being manufactured by M/s. Panacea Biotech Ltd., M/s. VHB Life Sciences Ltd. and M/s. Samarth Lifesciences. It has also been brought to the notice of this office that due to shortage of raw material from China, the supply of Penicillamine drug has been affected. In this regard, all three companies (mentioned above) have been asked to ensure sufficient availability of the said drug in the market.

Any person who requires the medicine may contact NPPA at
me.nppa2015@gmail.com or
Pharma Jan Samadhan at www.nppaindia.nic.in or
1800111255

so that NPPA can take up the matter with the manufacturers.


(Rakesh Kakkar)
Dy. Director(Cost)